Diabetes is a leading global health and economic challenge, affecting over 800 million people worldwide, with over 80% ...

Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most ...

BMO Capital Markets reaffirmed its “Market Perform” rating and $64.00 price target for Novo Nordisk A/S (NYSE:NVO) following ...

For patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease, 10-year data from the ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing ...

BURLINGAME, CA, UNITED STATES, May 20, 2025 /EINPresswire.com/ -- Biotechnology Market is estimated to be valued at USD 1,034.63 Bn in 2025 and is expected to reach USD 2,330.47 Bn in 2032, exhibiting ...

Contrarian investing advice from biotech and pharmaceutical stock expert Hartaj Singh, Founding Partner of Tecumseh Partners ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

Novo Nordisk A/S' CEO transition sparks governance concerns, but internal succession ensures stability. Click for my updated ...